Marksans Pharma Corporate Filings & Announcements

Latest corporate announcements and filings from Marksans Pharma on BSE

Search Inside the pdf :

Marksans Pharma Ltd.

26 Dec 2025

182.76

1.95%

SAST

Marksans Pharma Ltd - 524404 - Closure of Trading Window

BSE India

Intimation for closure of trading window for the quarter ended December, 2025

pdf

Marksans Pharma Ltd.

20 Nov 2025

182.76

1.95%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution from UK MHRA.

pdf

Marksans Pharma Ltd.

19 Nov 2025

182.76

1.95%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited''s wholly owned subsidiary Marksans Pharma Inc receives US FDA approval of its ANDA for Loperamide Hydrochloride 2mg tablets.

pdf

Marksans Pharma Ltd.

17 Nov 2025

182.76

1.95%

Company Update

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA.

pdf

Marksans Pharma Ltd.

17 Nov 2025

182.76

1.95%

Company Update

Marksans Pharma Ltd - 524404 - Newspaper Publication Of Financial Results For The Quarter And Half …

BSE India

Newspaper cuttings of unaudited financial results of the Company for the quarter and half year ended 30 September 2025 published in Business Standard (English) and Lakshadeep (Marathi) on 15 November 2025.

pdf